Hi-Tech Pharmacal settles patent litigation with MedPointe
Hi-Tech said that under the terms of the settlement and release agreement, the company will immediately cease distribution of its generic version of Tussi-12 DS and will also
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.